Introduction
The rapid development of new vaccines and new vaccine combinations, and the changing epidemiology of vaccinepreventable diseases, lead to a number of new vaccine recommendations annually. Providers must be aware of this information to effectively vaccinate their child and adolescent patients. The challenges in protecting the public from vaccine-preventable infections take many forms, including complex immunization schedules, increasing costs, and the emergence of vaccine hesitancy and antivaccination sentiment among some parents. This update on the 2010 childhood and adolescent immunization schedules and recent vaccine research addresses many of these challenges. It also provides support and recommendations for clinical practice in order to achieve or maintain high coverage levels, particularly in light of recent outbreaks of vaccine-preventable diseases. By addressing barriers to immunization, providers and parents can decrease morbidity and mortality from vaccine-preventable diseases.
Hepatitis B vaccine
The current recommendations for the prevention of hepatitis B (HBV) infection include universal infant vaccination beginning at birth and improved vaccine coverage among previously unvaccinated children and adolescents. The incidence of HBV infection and acute disease is highest among adults; however, chronic infection is more likely to occur in patients infected as infants or young children through perinatal transmission from infected mothers or horizontal transmission from infected household or other contacts. Before HBV vaccination programs began in the United States, about 30-40% of chronic HBV infections were believed to have resulted from perinatal or vertical transmission in early childhood [1] . Since implementation of routine childhood immunization, an estimated 6800 perinatal infections and an additional 18 700 infections during the first 10 years of life have been prevented annually in the United States [2] .
The National Health and Nutrition Examination Survey (NHANES) is conducted periodically to obtain data on the health status of the United States population at least 6 years of age. Survey data from the period 1999 to 2006 were compared with data from 1988 to 1994 to evaluate the effect of universal vaccination of infants, which began in 1991. In children aged 6-19 years of age, the prevalence of HBV infection decreased significantly from 1.9 to 0.6% and there was a 79% decrease in the age-adjusted prevalence of chronic infection from 0.24 to 0.05%, which was not statistically significant. The prevalence of anti-HBc, a marker of HBV infection, among US-born children 6-19 years of age (0.5%) did not differ by race or ethnicity. The disparity between anti-HBc prevalence in US-born and foreign-born children was smaller during 1999-2006 (0.5 vs. 2.0%) than during 1988-1994 (1.0 vs. 12.8%). Non-Hispanic blacks and 'Others' had a higher prevalence of past and present infection than non-Hispanic whites and Mexican Americans. Among children 6-19 years old, 56.7% had markers of vaccine-induced immunity. Thus, HBV prevalence has decreased among US children, reflecting the impact of global and domestic vaccination [3 ] .
As universal infant HBV vaccination has been implemented worldwide, endemic areas have seen dramatic decreases in seroprevalence rates. However, no randomized trials met the objectives of the review and inclusion criteria. Therefore, the conclusion is that there is no scientific evidence to support or refute the need for a booster dose of HepB in healthy individuals with normal immune status who fully responded to a complete course of vaccine [6] . Further studies will be necessary to determine the need for a booster dose of HepB.
Prior studies have noted lower antibody titers in vaccinated obese adolescents. Middleman et al. [7] reported an important new finding. Obese adolescents who received HepB through a 1.5-in. needle achieved higher antiHBs antibody titers compared with immunization with a 1-inch needle. Twenty-six patients 14-24 years old who weighed more than 90 kg for females and more than 120 kg for males and who had never received HepB were compared. All received injections at a 908 angle to the deltoid muscle, leaving 2-3 mm of needle visible between arm and hub. Though this was a small sample size, obese adolescents and young adults had significantly higher titers of anti-HBs after HepB when a 1. [8] .
Eighteen percent of rotavirus-positive patients in the Houston study were hospitalized. None of these patients had received a dose of RV5, indicating that vaccination conferred 100% protection against severe rotavirus disease requiring hospitalization. Three doses of RV5 were 95-97% effective against rotavirus AGE requiring intravenous hydration. RV5 is shown to be highly effective against severe rotavirus AGE, and even partial immunization confers substantial health benefits [9] . Not only was increased use of RV5 in a large pediatric practice in New Orleans, Louisiana, USA associated with a 50% decrease in rotavirus hospitalizations, but also the number of office visits for AGE decreased by 23%. A total of 16 000 children less than 5 years of age were followed. Concomitantly, during these years, there was a 67% decrease in rotavirus-positive ED visits or hospitalizations despite the fact that only 40-46% of eligible patients received at least one dose of RV5. In addition, children at least 2 years of age who were ineligible to receive RV5 also had a 41% decrease in rotavirus-related visits, demonstrating the herd immunity benefits of vaccination [13] .
Rotavirus vaccination has been beneficial in reducing physician visits and hospitalizations, reducing overall healthcare costs nationwide. Wang et al. [14 ] found complete vaccination with three doses of RV5 to be highly effective in preventing rotavirus infection and AGE, substantially reducing associated costs in the 2007-2008 season. Using a large, national health insurance claim database, a cohort of 33 140 infants who received three doses of RV5 were compared to a cohort of 26 167 infants who received three doses of diphtheria, tetanus and acellular pertussis (DTaP) but not RV5. Vaccine effectiveness against rotavirus gastroenteritis based on International Classification of Diseases, 9th revision (ICD-9) coding was 100%, and vaccine effectiveness against AGE was 59% in the hospital and ED settings. This translated to a 100% reduction in costs for rotavirus gastroenteritis hospitalization and ED visits and a 74% decrease in AGE-related hospitalization and ED visit costs. In the outpatient setting, vaccine effectiveness against rotavirus gastroenteritis was 96% and against AGE was 27%.
New York State hospital data also showed significant reductions in rotavirus gastroenteritis hospitalizations statewide in children less than 2 years old, reducing statewide hospital costs by US$ 10 million. In 2008, among children 1-23 months old, there was a 40% decrease in diarrhea-associated hospitalizations and 85% decrease in rotavirus-coded hospitalizations compared with previous years. Among children aged 24 months to 18 years, there was a 70-79% reduction in hospitalizations. These reductions were also seen in older children not eligible for vaccination [15] .
Despite an overall decline in hospitalization rates, some racial disparities in diarrhea-associated hospitalizations rates persist following vaccination, as demonstrated by Yen et al. [16] . Among all children less than 5 years of age, prevaccine (2000-2006) hospitalization rates were greater among whites than among blacks and Hispanics. Among infants less than 6 months old, black infants had higher rates of hospitalization, whereas white children at least 1 year old had higher rates of diarrheaassociated hospitalizations. After RV5 vaccination was introduced, racial disparities for children 12-35 months old resolved, but black infants less than 6 months old continued to have higher hospitalization rates. Higher rates of low birth weight and prematurity may lead to increased vulnerability of minority infants with greater risk of diarrheal complications. Race may be a proxy for socioeconomic status and environmental factors that increase the risk of infection, such as overcrowding and poor sanitation. Insurance status or level of maternal education may also lead to more severe disease because of a delay in seeking healthcare. These disparities remind clinicians of the importance of timely vaccination of all infants with rotavirus vaccine.
Internationally, rotavirus vaccination was proven to be highly effective as well. Field et al. [17] reported RV5 to be highly effective (vaccine efficacy of 89.3-93.9%) at preventing rotavirus hospitalizations in Australia. Within the first 12 months, Australia achieved a vaccine coverage rate of 73.1% for three doses of RV5 among the cohort of children eligible for vaccination. Three doses of RV5 were also highly effective (62.2-63.9%) in preventing nonrotavirus AGE hospitalizations in this cohort. The positive effects of the vaccine extended to unvaccinated children and adolescents, who also had reductions in rotavirus and nonrotavirus AGE admissions.
A study conducted in Israel found rotavirus vaccination was 50.1% effective in preventing AGE of all causes requiring a physician visit. Strain G1P [8] , covered in RV1, is the most common rotavirus strain causing hospitalization in Israel. A phase III trial of RV1 demonstrated an efficacy of 90.8% against severe rotavirus AGE caused by G1P [8] and 87.3% effectiveness against 63P [8] , G4P [8] , and G9P [8] [18] . In this particular study, 23% of children who received the RV1 before the 2008-2009 rotavirus season had at least one physician visit because of AGE during the 2008-2009 rotavirus season, compared with 46.7% among unvaccinated children, a vaccine effectiveness of 50.1% [19] .
Most clinicians are familiar with the withdrawal of RotaShield, a vaccine with simian-human reassortant strains of rotavirus with a high rate of replication in the human intestine, because of nine reports of intussusception among infants. RV5 is a pentavalent vaccine based on a bovine rotavirus strain with a low rate of replication in the human gastrointestinal tract. In a large phase III trial of over 70 000 infants in 11 countries, RV5 did not increase the risk of intussusception; six cases of intussusception were observed in the RV5 recipients, compared with five cases of intussusception in the placebo group.
Belongia et al. [20] performed a real-time monitoring study using continuous surveillance data from the Vaccine Safety Datalink population during a 2-year period to evaluate the relative risk for intussusception and other prespecified adverse events (seizures, meningitis/ encephalitis, myocarditis, Gram-negative sepsis, gastrointestinal bleeding, and Kawasaki syndrome). The observed frequency of adverse events after RV5 was compared with prelicensure background incidence rates to determine whether the observed number of events was greater than expected. A total of 207 621 doses of RV5 were administered to the study population. No elevation of risk was identified for intussusception or any other adverse event following administration of the first, second, or third dose of RV5. Five infants were identified by ICD-9 code for intussusception in a 30-day window after vaccination; however, only two of five cases were validated to have had intussusception by medical record review. Both cases were diagnosed more than 14 days after vaccine administration.
Patel et al. [21] reported three infants who developed dehydration and diarrhea within 1 month following their first or second rotavirus vaccination and subsequently received a diagnosis of severe combined immunodeficiency (SCID). RV5 contains reassortant rotavirus strains which are attenuated in their ability to replicate. Reverse transcription polymerase chain reaction (RT-PCR) analysis of DNA isolated from stool samples from all three of these infants revealed the same bovine rotavirus gene sequences contained in the vaccine, indicating that the infections were caused by the vaccine strain. Viral shedding after the administration of rotavirus vaccine has been detected in stool specimens 1-15 days after vaccination. In these three patients, rotavirus shedding persisted until 157, 197, and 362 days. Live viral vaccines are typically contraindicated in patients with immunodeficiencies; however, the rotavirus vaccine series is started at 2 months of age, before SCID is typically diagnosed. These case reports raise concern regarding the safety of rotavirus vaccines in severely immunocompromised patients. On the basis of these and other cases, SCID is now listed as a contraindication for rotavirus immunization. Neonatal screening for SCID and other T-cell deficiencies is being added to the routine newborn genetic screening panel. Once implemented, this should allow the detection of T-cellrelated immunodeficiencies before the first dose of rotavirus vaccine is administered.
Haemophilus influenzae type b conjugate vaccine
Haemophilus influenzae type b (Hib) was the leading cause of invasive bacterial disease in infants and children less than 5 years of age prior to the introduction of effective vaccines. Hib conjugate vaccine was licensed for use in 1990 [22] and has drastically changed the prevalence of Hib invasive disease.
On 13 December 2007, 1.2 million doses of Hib were voluntarily recalled by Merck (PedvaxHIB and COMVAX) because of routine testing that had identified Bacillus cereus in the vaccine manufacturing equipment but not in individual lots. Following the recall and the suspension of production of Merck Hib vaccine, in December 2007, the CDC issued interim recommendations to defer the 12-month to 15-month Hib vaccine booster, but to continue to provide the booster dose to children at high risk for invasive Hib disease. Infants 2-6 months of age were to continue to receive the recommended doses. The 12-month to 15-month booster dose was reinstated in June 2009 with the catch-up vaccination of children at their next routinely scheduled appointment or medical encounter [23] .
A report by Huang et al. [24] 
found no evidence of vaccine-associated B. cereus infection in recipients of recalled Hib vaccines on review of events involving recalled Hib vaccines received by the Vaccine Adverse Event Reporting System (VAERS) during April 2007 to February 2008 as well as postings on Epidemic Information Exchange (Epi-X).
Informing providers about interim recommendations during vaccine shortages is essential. Providers must be aware of and incorporate these recommendations into daily practice to successfully utilize remaining supplies to benefit the majority of children. Cooperation between practices and public health officials may also be required to distribute available vaccine where needed. An internet-based survey was conducted by Kempe et al. [25 ] to determine the knowledge of and adherence to the interim Hib recommendations. Ninety-eight percent of pediatricians and 81% of family physicians reported that they were aware of the recommendations. However, 22% of pediatricians and 33% of family physicians reported not deferring the booster dose. Physicians were less likely to adhere to the recommendations if their practice had sufficient vaccine supplies. A total of 73% of pediatricians and 45% of family physicians reported insufficient Hib supplies, with 22-24% deferring doses for infants 2-6 months of age at least 10% of the time. Now that the booster dose has been reinstated and catch-up booster doses are recommended at routinely scheduled visits, primary physicians must now focus on children who did not receive their booster dose through review of records before visits or targeted screening for children in certain age groups at the time of the visit. During times of shortages, practitioners must try to view the problems of shortages as a national rather than a practice-level issue so that the highest level of protection for individual children and for herd immunity is maintained during the shortage.
We are now able to observe the long-term effects of Hib vaccination. Hallander et al. [26] Ladhani et al. [27] conducted a study of long-term complications in children with Hib vaccine failure in the United Kingdom. There were 388 Hib vaccine failure cases in the United Kingdom, of whom nine died during the acute episode. Of the 260 families who returned the completed questionnaire, 18.5% of these children reported serious long-term sequelae. Of the children who experienced Hib vaccine failure, 18.8% had another serious infection requiring hospitalization and 7.7% had at least two serious infections. Children with other underlying conditions such as malignancies or immunodeficiencies were more likely to develop another serious infection. Among otherwise healthy children with Hib vaccine failure, 14.4% had a second serious infection. No child had another episode of invasive Hib disease. Given this relatively high rate of a second serious bacterial infection in children with Hib vaccine failure, practitioners should take special care in evaluating and monitoring these patients.
Immunoglobulin levels were obtained from 164 of these children and antibody concentrations against common pneumococcal serotypes were compared with age-matched controls. This study was done prior to the introduction of pneumococcal conjugate vaccine. For all ages combined, compared with controls, a higher proportion of cases had nonprotective antibody concentrations to certain pneumoccal serotypes. Younger children who had Hib vaccine failure were more likely to have nonprotective concentrations than age-matched controls. Among children less than 5 years old, the proportion of cases with nonprotective concentrations was significantly higher than age-matched controls for seven of nine serotypes. On the basis of these results, the authors speculate that children who have Hib vaccine failure may have a physiologic delay in their ability to develop protective antipolysaccharide antibody after exposure to encapsulated organisms, whether through colonization, immunization, or invasive infection [28] .
Pneumococcal vaccines (PCV7 and PCV13)
In February 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) was licensed by the Food and Drug Administration for children 6 weeks to 71 months old, replacing PCV7, which was licensed in 2000. In addition to the seven capsular antigens of Streptococcus pneumoniae serotypes in PCV7 (4, 6B, 9V, 14, 18C, 19F, and 23F) , PCV13 contains the capsular antigens of serotypes 1, 3, 5, 6A, 7F, 18C, and 19A. The ACIP recommends PCV13 vaccination of all children aged 2-59 months, children aged 60-71 months with underlying medical conditions that increase their risk for pneumococcal disease or complications, and infants and children who previously received one or more doses of PCV7 to complete the immunization series [29, 30] . A supplemental dose of PCV13 is also recommended for children fully immunized with PCV7: for healthy children, up to age 59 months, and for children with underlying medical conditions which increase their risk for invasive pneumococcal disease (IPD) or complications, through 71 months of age.
Serotype replacement
Several studies were published in 2010 describing the changing patterns of S. pneumoniae serotypes since the introduction of the pneumococcal vaccine in 2000. Following the introduction of the PCV7, overall incidence of IPD in children less than 5 years old decreased from approximately 99 cases per 100 000 during 1998-1999 to 21 cases per 100 000 in 2008, a reduction of 79%. IPD caused by the seven serotypes in PCV7 decreased by 99%; however, this decrease was offset by increases in IPD caused by nonvaccine serotypes [30] . As the patterns of pneumococcal serotypes continue to change as a result of pneumococcal vaccination, nonvaccine serotypes may cause an increasing number of episodes of invasive disease and local infections, such as otitis media and sinusitis.
Yildirim et al. [31] compared the strains of S. pneumoniae isolated from children less than 7 years of age in Massachusetts causing IPD and nasopharyngeal colonization in The first few years after PCV7, a shift in the predominant otopathogen among acute otitis media (AOM) prone children occurred from S. pneumoniae to nontypeable H. influenzae. Shortly after, a shift to non-PCV7 pneumococcal isolates was described, most recently to an antibiotic resistant serotype 19A. A prospective study of children 6-36 months old by Casey et al. [32] from 2007 to 2009, approximately 6-8 years after the introduction of PCV7 in the United States, found that vaccine serotypes have virtually disappeared from nasopharyngeal colonization and middle-ear fluid of vaccinated children. Children with infrequent AOM and AOM-prone children had nearly equal frequency of nontypeable H. influenzae and non-PCV7 S. pneumoniae serotypes, most commonly 19A. This was also the first US study to find no significant difference in the proportion of otopathogens from the middle-ear fluid or nasopharynx in children with their first or second AOM compared with AOM-prone children. Children who were prone to AOM had a greater frequency of isolation of penicillin nonsusceptible and beta-lactamase producing nontypeable H. influenzae. In this study, the proportion of S. pneumoniae isolated equaled that of nontypeable H. influenzae in AOM-prone children because of the rise of non-PCV7 serotypes. As PCV13 is being introduced, a positive impact on reducing the most common non-PCV7 serotypes, especially serotype 19A, can be expected.
Serotype 19A has become the leading causative serotype of IPD and the most frequently observed serotype in nasopharyngeal carriage after widespread implementation of PCV7 vaccination. Van Gils et al. [33] compared the nasopharyngeal acquisition of serotype 19A in 948 children who received a primary series of two doses of PCV7 and a booster dose (2 þ 1) of PCV7 or no vaccination. The proportion of children who tested positive for serotype 19A was highest in those who received 2 þ 1 dose PCV7 (16.2%) vs. those who were unvaccinated (9.2%). Antibiotic consumption did not differ between groups. Serotype 19A is already a frequent colonizer in unvaccinated children and it is suspected that the vacant niche created following PCV7 vaccination has allowed the expansion of 19A and other serotypes.
Serotype 6C is another emerging strain in the post-PCV7 era. Millar et al. [34] studied S. pneumoniae serotypes among certain native American populations who have high underlying rates of pneumococcal disease. Pneumococcal serotype 6C was first described in 2007 as distinctive from serotype 6A and has been found in increasing proportions among carriage and invasive isolates. This study, which spans 15 years and includes the periods prior to, during, and after the introduction of PCV7, found an association between PCV7 introduction and the emergence of serotype 6C. Although the rate increases of serotype 6C are minimal relative to the substantial decreases of serotypes 6B and 6A, the rates of invasive disease because of 6C have increased. The finding that, in the post-PCV7 era, serotype 6A has been dramatically reduced demonstrates that the serotype 6B antigen present in the PCV7 vaccine confers remarkable cross-protective immunity to serotype 6A. It is uncertain whether the 6A antigen present in PCV13 will protect against serotype 6C. We have discussed the impact of PCV vaccination on nasopharyngeal carriage and invasive disease serotypes. S. pneumoniae is recognized as a common cause of nonenteropathic hemolytic uremic syndrome (HUS) in children. Bender et al. [36] found an increasing frequency of streptococcus pneumoniae-associated hemolytic uremic syndrome (SP-HUS) at their medical center in Utah, which was specifically related to episodes of pneumonia and empyema. No children were identified with SP-HUS from 1971 to 1996, compared with seven children who had SP-HUS confirmed by culture from 1997 to 2008. Before 2000 and the introduction of PCV7, one of 352 children (0.3%) diagnosed with HUS had SP-HUS. After 2000, six of the 108 HUS patients (5.6%) had SP-HUS. Specifically, serotype 3, a frequent cause of complicated pneumonia post-PCV7, was associated with SP-HUS. The authors speculate that the increasing incidence of pneumococcal parapneumonic empyema described previously in different regions of the world after the introduction of PCV7 may account for the increase in HUS associated with S. pneumoniae.
Vaccine effectiveness
A Cochrane review confirmed the efficacy of PCV in preventing IPD, radiograph defined pneumonia, and clinical pneumonia among children less than 2 years old. This review included 11 randomized controlled trials of over 57 000 children who received PCV and 56 000 who received placebo or another vaccine in Africa, USA, Philippines, and Finland. Pooled vaccine efficacy for vaccine-type IPD was 80% and all-serotypes IPD was .58%. Vaccine efficacy against radiograph defined pneumonia was 27%, clinical pneumonia 6%, and allcause mortality 11% [37] .
Nasopharyngeal colonization of S. pneumoniae is frequent in early infancy through transmission from close contacts. Carriage of S. pneumoniae differs greatly between populations. Dagan et al. analyzed PCV7 vaccine hyporesponsiveness in southern Israel because of nasopharyngeal carriage of S. pneumoniae. In this prospective study, 545 infants were randomized to receive a three-dose primary vaccination and a booster dose (3 þ 1 group) or a two-dose primary vaccination with a booster (2 þ 1 group). At 2 months of age, 42% of infants in the 3 þ 1 group carried S. pneumoniae, of whom 18% carried a serotype included in PCV7. The 2 þ 1 group received the first dose of vaccine at 4 months of age, at which point 49% of infants carried S. pneumoniae, with 27% carriage of a serotype included in PCV7.
Carriage of PCV7 serotypes resulted in a decreased geometric mean concentration (GMC) of anticapsular IgG antibodies to the carried serotype, and a lower proportion of children had acceptable concentrations of antibody against the carried serotype in both groups after completion of the primary series. After the booster dose of PCV7 at 12 months of age, all groups showed a clear booster response; however, the serotype-specific GMCs were lower in children carrying the given serotype than those not carrying the serotype.
The authors speculate that the mechanism for this vaccine hyporesponsiveness is B-cell exhaustion or fatigue. B-cell hyporeponsiveness caused by injection of antigens has been previously described. Nasopharyngeal carriage during early infancy may result in absorption and circulation of polysaccharide antigen loads which bind to serotype-specific infant B cells which do not differentiate into antibody-producing plasma cells. This phenomenon persisted through the first year [38] .
A study by Vakevainen et al. conducted in the Philippines confirms the data that pneumococcal colonization at the time of vaccination interferes with immune response. PCV11, which contains polysaccharides of serotypes 1, 3, 4, 5, 7F, 14, 18C, 19F, and 23 F, was given at 6, 10, and 14 weeks. At 6 weeks of age, 28% of children carried pneumococcus on nasopharyngeal sampling. The GMC of antibodies 1 month after the third dose of PCV11 were significantly lower to specific serotypes among children who were carriers of that serotype than among children without carriage of that serotype. Immunization of these carriers with PCV11 results in concentrations of serotype-specific antibodies that are similar to those in unvaccinated children.
Hyporesponsiveness is an important finding which may have an impact in the developing world and in high-risk populations where a substantial proportion of infants are colonized with S. pneumoniae at a young age. Subsequent studies may be necessary to determine the optimal time to initiate pneumococcal immunization in these populations and whether additional booster doses may be required [39] .
PCV13
As mentioned above, IPD by nonvaccine serotypes has increased. IPD cases by serotype 19A in particular have risen by greater than 200%. On the basis of known serotype prevalences, 60-70% or more of the IPD in most regions of the world should be preventable with the use of PCV13.
The safety and tolerability of PCV13 are comparable to PCV7, as reported by Bryant et al. [40] . Tenderness, induration, and erythema were common with both vaccines. After the second dose, more PCV7 recipients than PCV13 recipients experienced significant tenderness that interfered with limb movement (8.5 vs. 1.8%). Systemic reactions of fever, decreased appetite, sleep changes, or irritability were more common after the first dose of vaccine and decreased with subsequent doses in both groups. No infants in either group experienced severe or life-threatening adverse events. PCV13 did not diminish the immune responses to concomitantly administered ActHib or to any of the antigens in Pediarix.
Esposito et al. [41 ] reported similar data regarding the safety of PCV13 compared with PCV7 in a study of 606 infants assigned to receive either PCV7 or PCV13. Overall, the safety profile of PCV13 was similar to that of PCV7. The percentage of children with reports of local reactions, systemic events, or antipyretic medication use was comparable between the two groups, except for irritability. which was reported more frequently in the PCV13 group than the PCV7 group after dose 1. There was no statistically significant difference between groups for incidence of serious adverse events after any of the doses. PCV13 did not adversely affect responses to concomitantly administered DTaP-HBV-IPV/Hib vaccine.
Both studies found that PCV13 is at least as immunogenic as PCV7 for the seven serotypes in common. PCV13 is immunogenic for the additional six serotypes as well. PCV13 is safe and immunogenic and should effectively supplant PCV7 for routine use in infants to provide broader coverage against current S. pneumoniae serotypes causing IPD.
Conclusion
This review has covered the latest research on the childhood and adolescent vaccines which are part of the annual harmonized immunization schedules of the Centers for Disease Control and Prevention (CDC), American Academy of Pediatrics (AAP), and the American Academy of Family Practice (AAFP). Vaccines play a fundamental role in the health promotion and disease prevention of all children. Ongoing improvements in maximizing coverage rates are critical to limiting the impact of infectious diseases.
